Immune oncology, immune responsiveness and the theory of everything

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

(2017) Leisha A. Emens et al.   EUROPEAN JOURNAL OF CANCER

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy

(2017) Yemsratch T. Akalu et al.   IMMUNOLOGICAL REVIEWS

Neoepitopes as cancer immunotherapy targets: key challenges and opportunities

(2017) Cory A Brennick et al.   Immunotherapy

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

(2017) Giuseppe V. Masucci et al.   Journal of Translational Medicine

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis

(2017) Kelby W. Wegner et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

(2017) Dennis O. Adeegbe et al.   Cancer Discovery

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

(2017) Pornpimol Charoentong et al.   Cell Reports

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models

(2017) William K. Decker et al.   Frontiers in Immunology

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

(2017) Wouter Hendrickx et al.   OncoImmunology

Indicators of responsiveness to immune checkpoint inhibitors

(2017) Bradley D. Shields et al.   Scientific Reports

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Innate immune signaling and regulation in cancer immunotherapy

(2016) Leticia Corrales et al.   CELL RESEARCH

Regulated cell death and adaptive stress responses

(2016) Lorenzo Galluzzi et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The DNA damage-induced cell death response: a roadmap to kill cancer cells

(2016) Sonja Matt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines

(2016) O. Tu reci et al.   CLINICAL CANCER RESEARCH

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer

(2016) Stephen M Hatfield et al.   CURRENT OPINION IN PHARMACOLOGY

Serum and glucocorticoid kinase 1 promoted the growth and migration of non-small cell lung cancer cells

(2016) Yu Xiaobo et al.   GENE

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

Mer receptor tyrosine kinase negatively regulates lipoteichoic acid-induced inflammatory response via PI3K/Akt and SOCS3

(2016) Bing Zhang et al.   MOLECULAR IMMUNOLOGY

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy

(2016) Lorenzo Galluzzi et al.   Nature Reviews Clinical Oncology

The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation

(2016) Aleksander M. Grabiec et al.   Seminars in Immunopathology

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Analysis of PI3K pathway components in human cancers

(2016) JAMILA DARAGMEH et al.   Oncology Letters

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy

(2016) Marka R. Crittenden et al.   Oncotarget

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness

(2016) L. D. Miller et al.   Cancer Immunology Research

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk

(2016) Elise P. Salerno et al.   OncoImmunology

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

(2015) Elin Karlsson et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic and predictive immune gene signatures in breast cancer

(2015) Davide Bedognetti et al.   CURRENT OPINION IN ONCOLOGY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP

(2015) Eyad Elkord et al.   Oncotarget

Tumor-intrinsic oncogene pathways mediating immune avoidance

(2015) Stefani Spranger et al.   OncoImmunology

Role of Local Radiation Therapy in Cancer Immunotherapy

(2015) Sandra Demaria et al.   JAMA Oncology

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

(2015) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

NOD-scidIl2rg tm1Wjl and NOD-Rag1 null Il2rg tm1Wjl : A Model for Stromal Cell–Tumor Cell Interaction for Human Colon Cancer

(2014) Justin Maykel et al.   DIGESTIVE DISEASES AND SCIENCES

Melanoma NOS1 expression promotes dysfunctional IFN signaling

(2014) Qiuzhen Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Fibroblast heterogeneity in the cancer wound

(2014) Daniel Öhlund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phagocytosis of apoptotic or necrotic cells differentially regulates the transcriptional expression of IL-12 family members in dendritic cells

(2014) K. O. Dixon et al.   JOURNAL OF LEUKOCYTE BIOLOGY

PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis

(2014) M R Spalinger et al.   Mucosal Immunology

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

(2013) Jérôme Galon et al.   IMMUNITY

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model

(2013) Stefanie Kirchberger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A balance of interleukin-12 and -23 in cancer

(2013) Shin Foong Ngiow et al.   TRENDS IN IMMUNOLOGY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

(2013) Srikanth Nagalla et al.   GENOME BIOLOGY

The stable traits of melanoma genetics: an alternate approach to target discovery

(2012) Tara L Spivey et al.   BMC GENOMICS

IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+Th17 cells

(2012) Margherita Coccia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression of NF-κB p50 in Tumor Stroma Limits the Control of Tumors by Radiation Therapy

(2012) Marka R. Crittenden et al.   PLoS One

A genetic inference on cancer immune responsiveness

(2012) Ena Wang et al.   OncoImmunology

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

(2011) Marie Tosolini et al.   CANCER RESEARCH

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase

(2010) Elina Mattila et al.   BMC CANCER

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

(2009) D. D. Vo et al.   CANCER RESEARCH

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

The immunologic constant of rejection

(2008) Ena Wang et al.   TRENDS IN IMMUNOLOGY

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE